What is Zosano Pharma Corporation's current stock price?

Zosano Pharma Corporation (ZSAN) currently trades at USD 0.5576. Track real-time price changes and historical performance on AllInvestView.

What sector is Zosano Pharma Corporation in?

Zosano Pharma Corporation operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Zosano Pharma Corporation ZSAN · Stock Open Zosano Pharma Corporation in new tab

0.5576 USD

Add to portfolio

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Zosano Pharma Corporation (ZSAN)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Zosano Pharma Corporation Analysis (ZSAN)

United States Health Care Official Website Stock

Is Zosano Pharma Corporation a good investment? Zosano Pharma Corporation (ZSAN) is currently trading at 0.5576 USD.

Investor FAQ

Does Zosano Pharma Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zosano Pharma Corporation?

Zosano Pharma Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Exchange Ticker

NMS (United States) ZSAN

Trades

No dividend information available for this instrument.

Zosano Pharma Corporation ZSAN · Stock Open Zosano Pharma Corporation in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Zosano Pharma Corporation Analysis (ZSAN)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Zosano Pharma Corporation ZSAN · Stock Open Zosano Pharma Corporation in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Zosano Pharma Corporation Analysis (ZSAN)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications